Lisbon Portugal | 1st April 2013


Isogenica announce their sponsorship of PEGS 2013, one of the largest protein engineering events, taking place at the Seaport World Trade Center in Boston between April 29 and May 3.  PEGS provides Isogenica with the ideal platform from which to promote Colibra™, its new controlled ratio gene library build technology, which enables protein engineers to specify the critical antibody and peptide diversity that underpins approaches to new product discovery.

Delegates are invited to join the Isogenica team throughout the week, at Booth 218 in the main exhibition hall, to discover more about the ratio control capabilities of the new Colibra™ libraries, and to discuss the application of its synergistic CIS Display in rapid selection from very large, diverse gene libraries.  On Wednesday May 1st at 12:40pm, Chris Ullman, Isogenica’s CSO, will lead an expert session: “Challenges in Synthetic Antibody Design using Combinatorial Libraries” which will include a short talk by one of Isogenica’s pharmaceutical collaborators.


“The PEGS event is a fantastic opportunity to meet the protein engineering community and share our latest technology developments with them.  Colibra™ has been well received by the market and we are seeing greater interest from commercial companies that want to use CIS Display.  Because of this we are expanding operations and recruiting to keep up with demand.” said Kevin Mathews, CEO of Isogenica


Note to Editors


Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technologies, CIS display and Colibra™.  Founded in 2000, Isogenica is able to offer high quality customised gene libraries and rapid selection studies for application in protein engineering and product discovery.  Isogenica’s CIS display technology is an in vitro display technology that allows the rapid generation of polypeptide and antibody libraries from which it is possible to select lead molecules with high affinity and specificity for most targets.